• Something wrong with this record ?

Longitudinal Monitoring of Hair Cortisol Using Liquid Chromatography-Mass Spectrometry to Prevent Hypercortisolism in Patients Undergoing Glucocorticoid Replacement Therapy

K. Kostolanská, H. Šiprová, E. Bartečků, J. Juřica, I. Řiháček, E. Táborská, M. Souček, O. Peš

. 2022 ; 44 (3) : 438-447. [pub] 20220601

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22018272

OBJECTIVE: Currently available methods for endogenous cortisol monitoring in patients with hormonal insufficiency rely on measurements of plasma levels only at a single time point; thus, any kind of chronic exposure to cortisol is challenging to evaluate because it requires collecting samples at different time points. Hair cortisol levels acquired longitudinally better reflected chronic exposure (both cortisol synthesis and deposition) and may significantly contribute to better outcomes in glucocorticoid replacement therapies. DESIGN: Twenty-two patients on cortisol substitution therapy were monitored for plasma, urinary, and hair cortisol levels for 18 months to determine whether hair cortisol may serve as a monitoring option for therapy setting and adjustment. METHODS: Plasma and urinary cortisol levels were measured using standardized immunoassay methods, and segmented (∼1 cm) hair cortisol levels were monitored by liquid chromatography coupled to mass spectrometry. A log-normal model of the changes over time was proposed, and Bayesian statistics were used to compare plasma, urinary, and hair cortisol levels over 18 months. RESULTS AND CONCLUSIONS: Hair cortisol levels decreased over time in patients undergoing substitutional therapy. The residual variance of hair cortisol in comparison to plasma or urinary cortisol levels was much lower. Thus, longitudinal monitoring of hair cortisol levels could prove beneficial as a noninvasive tool to reduce the risk of overdosing and improve the overall patient health.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018272
003      
CZ-PrNML
005      
20230102150054.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/FTD.0000000000000946 $2 doi
035    __
$a (PubMed)35550494
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kostolanská, Katarína $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Longitudinal Monitoring of Hair Cortisol Using Liquid Chromatography-Mass Spectrometry to Prevent Hypercortisolism in Patients Undergoing Glucocorticoid Replacement Therapy / $c K. Kostolanská, H. Šiprová, E. Bartečků, J. Juřica, I. Řiháček, E. Táborská, M. Souček, O. Peš
520    9_
$a OBJECTIVE: Currently available methods for endogenous cortisol monitoring in patients with hormonal insufficiency rely on measurements of plasma levels only at a single time point; thus, any kind of chronic exposure to cortisol is challenging to evaluate because it requires collecting samples at different time points. Hair cortisol levels acquired longitudinally better reflected chronic exposure (both cortisol synthesis and deposition) and may significantly contribute to better outcomes in glucocorticoid replacement therapies. DESIGN: Twenty-two patients on cortisol substitution therapy were monitored for plasma, urinary, and hair cortisol levels for 18 months to determine whether hair cortisol may serve as a monitoring option for therapy setting and adjustment. METHODS: Plasma and urinary cortisol levels were measured using standardized immunoassay methods, and segmented (∼1 cm) hair cortisol levels were monitored by liquid chromatography coupled to mass spectrometry. A log-normal model of the changes over time was proposed, and Bayesian statistics were used to compare plasma, urinary, and hair cortisol levels over 18 months. RESULTS AND CONCLUSIONS: Hair cortisol levels decreased over time in patients undergoing substitutional therapy. The residual variance of hair cortisol in comparison to plasma or urinary cortisol levels was much lower. Thus, longitudinal monitoring of hair cortisol levels could prove beneficial as a noninvasive tool to reduce the risk of overdosing and improve the overall patient health.
650    _2
$a Bayesova věta $7 D001499
650    _2
$a chromatografie kapalinová $7 D002853
650    12
$a Cushingův syndrom $x farmakoterapie $7 D003480
650    _2
$a glukokortikoidy $x terapeutické užití $7 D005938
650    _2
$a vlasy, chlupy $x chemie $7 D006197
650    _2
$a lidé $7 D006801
650    12
$a hydrokortison $x analýza $7 D006854
650    _2
$a tandemová hmotnostní spektrometrie $7 D053719
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Šiprová, Helena $u Endocrinology Ambulance, St. Anne's University Hospital, Brno, Czech Republic
700    1_
$a Bartečková, Eliška, $u Department of Psychiatry, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic; and $d 1982- $7 xx0244861
700    1_
$a Juřica, Jan $u Department of Pharmacology and Toxicology, Pharmaceutical Faculty, Faculty of Medicine, Masaryk University, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Řiháček, Ivan $u Endocrinology Ambulance, St. Anne's University Hospital, Brno, Czech Republic
700    1_
$a Táborská, Eva $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Souček, Miroslav $u Endocrinology Ambulance, St. Anne's University Hospital, Brno, Czech Republic
700    1_
$a Peš, Ondřej $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000213250418
773    0_
$w MED00004503 $t Therapeutic drug monitoring $x 1536-3694 $g Roč. 44, č. 3 (2022), s. 438-447
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35550494 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20230102150052 $b ABA008
999    __
$a ok $b bmc $g 1822055 $s 1169515
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 44 $c 3 $d 438-447 $e 20220601 $i 1536-3694 $m Therapeutic drug monitoring $n Ther Drug Monit $x MED00004503
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options